CAR-T Meeting 2026 | The 10-year experience of CD22 CAR T-cells for children and young adults with B-ALL
Alexandra Dreyzin, MD, National Institutes of Health, Bethesda, MD, provides insight into a 10-year study (NCT02315612) investigating CD22-targeting CAR T-cells in children and young adults with B-cell acute lymphoblastic leukemia (B-ALL), highlighting lessons learned about the therapy’s efficacy and the management of treatment-related toxicities. Dr Dreyzin notes that correlative data from the trial have identified biological features of T-cells that correlate with response, which could serve as a predictive marker. This interview took place at the EBMT-EHA 8th European CAR T-cell Meeting, held in Palma de Mallorca, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
This was obviously a very long trial, and I was lucky enough to be a part of it toward the end and to pull this data together. Some of the lessons that came out of CD22 were looking at toxicities. So we learned a lot about IEC-HS, immune effector cell-mediated HLH-like toxicity, and we learned a lot about managing IEC-HS, including a preemptive management strategy where we start steroids and anakinra early and using the emapalumab to mitigate toxicities, and that’s something that we’re using now in the bicistronic trial as well...
This was obviously a very long trial, and I was lucky enough to be a part of it toward the end and to pull this data together. Some of the lessons that came out of CD22 were looking at toxicities. So we learned a lot about IEC-HS, immune effector cell-mediated HLH-like toxicity, and we learned a lot about managing IEC-HS, including a preemptive management strategy where we start steroids and anakinra early and using the emapalumab to mitigate toxicities, and that’s something that we’re using now in the bicistronic trial as well. We’ve learned a lot about the efficacy of the CAR in the setting of both high and low disease burden. And then we have a lot of really interesting correlative data from the CD22 trial, including looking at properties of both the infusion product and the apheresis material and identifying features of the T-cells that really correlate with response. And similar to other studies, what we have seen is that naive cells and early memory cells do tend to cluster in patients who have a complete response and that could be potentially used as a predictive marker.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
